Thursday, 23 January 2020

Orexigen to be sold to Nalpropion Pharma for $75M

24 April 2018 | News

Nalpropion is a newly formed special purpose entity capitalized by an investor group that includes Pernix Therapeutics.

Singapore – Orexigen, a California-based pharmaceutical company focused on development of treatments for obesity announced that it has inked an agreement with Nalpropion Pharmaceuticals to sell virtually all of its assets for $75M in cash.

Nalpropion is a newly formed special purpose entity capitalized by an investor group that includes Pernix Therapeutics. Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. 

The transaction is subject to higher/better offers.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is 2020 demanding timely action of technology adoption in healthcare?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls